PTGFR and retinal disorder: To determine the potential therapeutic effect of targeting the PGF2α/PTGFR axis in proliferative retinopathy, AL8810, a selective inhibitor of PTGFR, was administered to OIR mice at the vessel proliferation stage (days 12–17), twice per day (Fig 8A).